Clinical Trial Update: Relative Bioavailability Study of HNC364 Injectable Suspension [Phase 1]

View source ↗

Summary

Phase 1 relative bioavailability study of HNC364 Injectable Suspension for Parkinson's disease, sponsored by Guangzhou Henovcom Bioscience Co. Ltd.; status is N…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• HNC364 Injectable Suspension (HNC364)

Snippet

Sponsor: Guangzhou Henovcom Bioscience Co. Ltd. | Conditions: Parkinson's Disease (PD) | Phase 1 | Status: NOT_YET_RECRUITING